CDTX - NASDAQ

Cidara Therapeutics, Inc.

CDTX·NASDAQ

$221.38

+0.0000%

HealthcareBiotechnology

Cidara Therapeutics, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of long-acting anti-infectives for the treatment and prevention of infectious diseases and oncology in the United States. The company's lead product candidate is rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of invasive fungal infections, including candidemia and invasive candidiasis, which are fungal infections associated with high mortality rates. It also advances its Cloudbreak platform to develop conjugates for the prevention and treatment of influenza and other viral infections, such as RSV, HIV, and the SARS-CoV-2 strains causing COVID-19. The company was formerly known as K2 Therapeutics, Inc. and changed its name to Cidara Therapeutics, Inc. in July 2014. Cidara Therapeutics, Inc. was incorporated in 2012 and is based in San Diego, California.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$5.61B

EPS-26.7500

P/E Ratio-8.28

Earnings Date03/05/2026

214.80M

Assets

220%

3Y+185.0%

5Y+211.0%

10Y+95.0%

51.49M

Total Liabilities

-32%

3Y-4.0%

5Y+65.0%

10Y+749.0%

163.31M

Total Equity

-2089%

3Y+657.0%

5Y+332.0%

10Y+57.0%

Cidara Therapeutics, Inc. Funding & Solvency Profile

CDTX · NASDAQ

Current Assets

Cash & Cash Equivalents189.82M

Net Receivables1.69M

Inventory0.00

Other Current Assets19.22M

Total Current Assets211 M

Non-Current Assets

Property, Plant & Equipment3.96M

Goodwill & Intangible Assets0.00

Long-Term Investments0.00

Other Non-Current Assets96.00K

Total Non-Current Assets4 M

Total Assets

214.80M

Financial Health Analysis

Current Ratio

4.25x

Excellent liquidity position. The company can easily cover its short-term obligations with substantial cushion.

Debt-to-Equity Ratio

0.32x

Conservative capital structure. The company relies primarily on equity financing, indicating low financial risk.

Working Capital

161 M

Strong working capital position provides significant operational flexibility and financial cushion.

Asset Composition

98% Current

Asset-light business model with high liquidity. Majority of assets are easily convertible to cash.

Financial Health Insight

Strong financial foundation: Excellent liquidity combined with conservative leverage suggests the company is well-positioned to weather economic uncertainties and fund growth opportunities.

Cidara Therapeutics, Inc. Balance Sheet

CDTX • NASDAQ

Cidara Therapeutics, Inc. Balance Sheet	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019	Dec 2018	Dec 2017	Dec 2016	Dec 2015	Dec 2014	Dec 2013	Dec 2012
ASSETS
CURRENT ASSETS
Cash and Cash Equivalents	189.8M	35.8M	32.7M	62.3M	35.9M	50.3M	74.6M	75.3M	104.6M	107.5M	22.8M	185K	1K
Cash & Short-Term Investments	189.8M	35.8M	32.7M	62.3M	35.9M	50.3M	74.6M	75.3M	104.6M	107.5M	22.8M	185K	1K
Net Receivables	1.7M	16.2M	5.8M	5.4M	11.2M	10K	0.0	321K	0.0	0.0	0.0	0.0	0.0
Accounts Receivables	1.7M	16.2M	5.8M	5.4M	11.2M	10K	0.0	321K	0.0	0.0	0.0	0.0	0.0
Inventory	0.0	6.1M	0.0	-2.6M	0.0	0.0	0.0	-321K	0.0	0.0	0.0	0.0	0.0
Prepaids	0.0	0.0	6.5M	4.1M	3.1M	5.5M	0.0	2M	779K	704K	217K	13K	0.0
Other Current Assets	19.2M	2.7M	0.0	2.6M	7M	10M	2.6M	0.0	779K	704K	0.0	0.0	0.0
Total Current Assets	210.7M	60.9M	45.1M	71.7M	57.2M	65.8M	77.1M	77.7M	105.4M	108.2M	23M	198K	1K
NON-CURRENT ASSETS
Property, Plant, and Equipment (Net)	4M	5.1M	1.3M	2.5M	1.2M	2.1M	712K	1M	1.4M	1.7M	863K	0.0	0.0
Tax Assets	0.0	0.0	0.0	551K	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Other Non-Current Assets	96K	1M	1.1M	533K	2M	1.1M	1.3M	321K	190K	72K	474K	3K	0.0
Total Non-Current Assets	4.1M	6.2M	2.4M	3.6M	3.2M	3.2M	2M	1.4M	1.6M	1.8M	1.3M	3K	0.0
Total Assets	214.8M	67M	47.5M	75.3M	60.4M	69M	79.1M	79M	107M	110M	24.4M	201K	0.0
LIABILITIES
CURRENT LIABILITIES
Total Payables	3.6M	3.8M	13M	1.3M	4.6M	1.9M	2.8M	2.6M	2.9M	3.1M	1.2M	32K	0.0
Accounts Payable	3.6M	3.8M	1.4M	1.3M	4.6M	1.9M	2.8M	2.6M	2.9M	3.1M	1.2M	32K	0.0
Other Payables	0.0	0.0	11.5M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Accrued Expenses	0.0	5M	7.7M	4.9M	8M	4.1M	2.8M	6.8M	6M	2.9M	2M	84K	0.0
Short Term Debt	0.0	0.0	0.0	2.6M	7M	10M	9.9M	2.7M	0.0	0.0	0.0	0.0	0.0
Capital Lease Obligations (Current)	1.6M	1.3M	1.2M	1.1M	939K	818K	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Tax Payables	26M	18M	11.5M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Deferred Revenue	0.0	25.1M	14.6M	13.9M	13.9M	9.8M	6.7M	0.0	0.0	0.0	0.0	0.0	0.0
Other Current Liabilities	44.3M	32.2M	4.9M	10.2M	4.2M	3.7M	4.3M	0.0	0.0	0.0	0.0	0.0	80K
Total Current Liabilities	49.6M	67.4M	41.4M	34M	38.6M	30.2M	19.9M	12.1M	8.9M	6M	3.2M	116K	80K
NON-CURRENT LIABILITIES
Long Term Debt	0.0	0.0	0.0	0.0	0.0	0.0	0.0	7.2M	9.8M	0.0	0.0	1.5M	0.0
Deferred Revenue (Non-Current)	0.0	4.2M	20.5M	18.4M	11.1M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Other Non-Current Liabilities	0.0	0.0	0.0	0.0	0.0	0.0	81K	0.0	80K	88K	34K	0.0	0.0
Total Non-Current Liabilities	1.9M	7.8M	20.5M	19.7M	11.1M	942K	81K	7.2M	9.9M	6.1M	34K	1.5M	0.0
Other Liabilities	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-6M	0.0	0.0	0.0
Capital Lease Obligations	3.6M	4.9M	1.2M	2.5M	939K	1.8M	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Total Liabilities	51.5M	75.2M	61.9M	53.8M	49.7M	31.1M	20M	19.3M	18.8M	6.1M	3.2M	1.6M	80K
SHAREHOLDERS' EQUITY
Preferred Stock	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	110M	32.5M	0.0	0.0
Common Stock	1K	9K	7K	7K	4K	3K	3K	2K	2K	1K	0.0	0.0	1K
Additional Paid-In Capital	774.6M	433.2M	404.1M	398.7M	345.4M	297.7M	277.9M	209.1M	181.8M	149.4M	1.9M	12K	0.0
Retained Earnings	-611.3M	-441.4M	-418.5M	-377.2M	-334.7M	-259.8M	-218.7M	-149.4M	-93.7M	-45.5M	-13.3M	-1.4M	-66K
Accumulated Other Comprehensive Income/Loss	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-8K	-1K	-8K	-179K	0.0	0.0
Total Stockholders' Equity	163.3M	-8.2M	-14.4M	21.6M	10.7M	37.8M	59.1M	59.7M	88.2M	103.9M	21.1M	-1.4M	-65K
Total Equity	163.3M	-8.2M	-14.4M	21.6M	10.7M	37.8M	59.1M	59.7M	88.2M	103.9M	21.1M	-1.4M	-65K
SUMMARY
Total Liabilities & Equity	214.8M	67M	47.5M	75.3M	60.4M	69M	79.1M	79M	107M	110M	24.4M	201K	0.0
Total Debt	3.6M	4.9M	1.2M	5.1M	8M	11.7M	9.9M	9.9M	9.8M	0.0	0.0	1.5M	0.0
Net Debt	-186.2M	-30.9M	-31.5M	-57.2M	-28M	-38.5M	-64.6M	-65.4M	-94.8M	-107.5M	-22.8M	1.3M	-1K
Shares Outstanding	25,358,100	25,358,100	25,358,100	25,358,100	25,358,100	25,358,100	25,358,100	25,358,100	25,358,100	25,358,100	25,358,100	25,358,100	25,358,100

SEC Filings

CDTX - Filing history and reports

Filing Type	Filing Date	Period Ending	Fiscal Year	Actions
8-K 8-K 2026 N/A	January 07, 2026	January 07, 2026	2026	View Filing
8-K 8-K 2025 N/A	November 14, 2025	November 13, 2025	2025	View Filing
10-Q 10-Q 2025 Q3 Q3	November 06, 2025	September 30, 2025	2025	View Filing
8-K 8-K 2025 N/A	November 06, 2025	November 06, 2025	2025	View Filing
8-K 8-K 2025 N/A	October 06, 2025	September 30, 2025	2025	View Filing
8-K 8-K 2025 N/A	September 24, 2025	September 24, 2025	2025	View Filing
10-Q 10-Q 2025 Q2 Q2	August 07, 2025	June 30, 2025	2025	View Filing
8-K 8-K 2025 N/A	August 07, 2025	August 07, 2025	2025	View Filing
8-K 8-K 2025 N/A	June 25, 2025	June 24, 2025	2025	View Filing
8-K 8-K 2025 N/A	June 24, 2025	June 24, 2025	2025	View Filing

Showing 1 to 10 of 223 filings

Related Guides

Blog Categories

Continue your CDTX research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.